AKT1 and breast cancer: The same observation has been reported by Meric-Bernstam et al., who showed that rapamycin treatment is associated with increased p-AKT in sensitive breast cancer models in vitro and in vivo, indicating that treatment-associated increase in P-AKT is not a marker of resistance but rather of sensitivity [31].